SC dismisses plea for centre-wise data of anti-diarrhoea vaccine trial

Q: How long will it take to read this news story?

The story "SC dismisses plea for centre-wise data of anti-diarrhoea vaccine trial" has 439 words across 14 sentences, which will take approximately 2 - 4 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "SC dismisses plea for centre-wise data of anti-diarrhoea vaccine trial" was covered 11 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 319 news stories per day. It's most recent story was published 4 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #21956311</li><li>URL: https://beamstart.com/news/sc-dismisses-plea-for-centre-17229455629181</li></ul>

Business Standard Logo Business Standard 11h ago

SC dismisses plea for centre-wise data of anti-diarrhoea vaccine trial - Business Standard

Quick Summary:

A bench of justices B R Gavai and K V Viswanathan passed the order while hearing a plea seeking directions to the Centre and others to make public the "segregated data" on the results of third phase of clinical trial of Rotavac involving 6,799 infants.

The Supreme Court on Tuesday dismissed a plea seeking centre-wise data of the clinical trial of anti-diarrhoea vaccine Rotavac, saying it cannot sit in appeal over the decision taken by an expert committee on the issue.

The plea had stated the trials were conducted at three centres at Delhi, Pune and Vellore to gauge the safety and efficacy of the vaccine.